Several other equities analysts have also recently issued reports on the stock. CIBC reduced their price target on shares of Aurora Cannabis from C$9.25 to C$6.50 in a research report on Thursday, February 3rd. Zacks Investment Research upgraded Aurora Cannabis from a “sell” rating to a “hold” rating in a research report on Monday, January 31st. Three investment analysts have rated the stock with a sell rating and seven have issued a hold rating to the company’s stock. According to MarketBeat, the company has an average rating of “Hold” and an average target price of $6.45.
ACB stock traded up $0.32 during trading on Friday, hitting $2.74. 615,285 shares of the company traded hands, compared to its average volume of 5,188,879. The firm has a market capitalization of $614.66 million, a PE ratio of -1.74 and a beta of 2.86. Aurora Cannabis has a 1 year low of $2.20 and a 1 year high of $10.64. The company has a 50-day moving average of $3.39 and a 200-day moving average of $4.85. The company has a debt-to-equity ratio of 0.19, a quick ratio of 3.70 and a current ratio of 4.92.
Aurora Cannabis (NYSE:ACB – Get Rating) last announced its earnings results on Thursday, February 10th. The company reported ($0.42) EPS for the quarter, missing analysts’ consensus estimates of ($0.17) by ($0.25). The business had revenue of $48.07 million for the quarter, compared to the consensus estimate of $45.87 million. Aurora Cannabis had a negative net margin of 167.83% and a negative return on equity of 11.52%. Sell-side analysts expect that Aurora Cannabis will post -0.8 EPS for the current year.
A number of institutional investors and hedge funds have recently modified their holdings of the business. Ausdal Financial Partners Inc. purchased a new position in shares of Aurora Cannabis in the 4th quarter worth $3,465,000. Merlin Capital LLC purchased a new position in shares of Aurora Cannabis in the 4th quarter worth $2,110,000. JPMorgan Chase & Co. boosted its stake in shares of Aurora Cannabis by 824.7% in the 1st quarter. JPMorgan Chase & Co. now owns 371,269 shares of the company’s stock worth $1,485,000 after buying an additional 331,120 shares during the last quarter. Dimensional Fund Advisors LP boosted its stake in shares of Aurora Cannabis by 47.1% in the 1st quarter. Dimensional Fund Advisors LP now owns 981,039 shares of the company’s stock worth $3,924,000 after buying an additional 313,940 shares during the last quarter. Finally, Mirabella Financial Services LLP purchased a new position in shares of Aurora Cannabis in the 4th quarter worth $1,461,000. Institutional investors and hedge funds own 15.47% of the company’s stock.
About Aurora Cannabis (Get Rating)
Aurora Cannabis Inc produces, distributes, and sells cannabis and cannabis derivative products in Canada and internationally. It also engages in facility engineering and design, cannabis breeding, research, production, derivatives, product development, wholesale, and retail distribution activities. The company produces various strains of dried cannabis, cannabis oil and capsules, and topical kits for medical patients.
This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest and most accurate reporting. This story was reviewed by MarketBeat’s editorial team prior to publication. Please send any questions or comments about this story to [email protected]
Before you consider Aurora Cannabis, you’ll want to hear this.
MarketBeat keeps track of Wall Street’s top-rated and best performing research analysts and the stocks they recommend to their clients on a daily basis. MarketBeat has identified the five stocks that top analysts are quietly whispering to their clients to buy now before the broader market catches on… and Aurora Cannabis wasn’t on the list.
While Aurora Cannabis currently has a “Hold” rating among analysts, top-rated analysts believe these five stocks are better buys.